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Amyotrophic lateral sclerosis (ALS) is a motor neuron disease characterized by
degeneration and loss of upper and lower motor neurons from the motor cortex,
brainstem and spinal cord although evidence is suggesting that there is further
involvement of other cell types in the surrounding tissue. Transcriptomic analysis by
gene expression profiling using microarray technology has enabled the determination
of patterns of cell death in the degenerating tissues. This work has examined gene
expression at the level of the tissue and individual cell types in both sporadic and
familial forms of the disease. In addition, further studies have examined the differential
vulnerability of neuronal cells in different regions of the central nervous system. Model
systems have also provided further information to help unravel the mechanisms that lead
to death of the motor neurons in disease and also provided novel insights. In this review
we shall describe the methods that have been used in these investigations and describe
how they have contributed to our knowledge of the cell death mechanisms in ALS.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is described as a degenerative
disease involving loss of the upper and lower motor neurons
from motor cortex, brain stem and spinal cord leading to muscle
denervation, wasting and death. There is now increasing evidence
that other cell types are involved and the precise pattern of
degeneration is unclear (Ince et al., 2011). Multiple mutually
compatible mechanisms have been implicated in the pathogenesis
of the disease including oxidative stress, excitotoxicity, ubiqui-
tin and proteasome dysfunction, inflammatory activation, RNA
processing dysregulation, mitochondrial dysfunction, cytoskeletal
abnormalities and activation of apoptosis (Ferraiuolo et al., 2011).
However, there remain many unanswered questions as to the
origins of the disease and the precise pathogenetic mechanism.
The use of microarray technology to explore gene expression at
a particular time point and in particular cells is enabling us to
unpick some of the specific changes undergone by cells or tissues
involved in the disease and also to determine what processes act
to protect cells from degeneration. The technology for different
array types has been described and reviewed previously and we
will not at this time extend this (Clark et al., 2007; Kirby et al.,
2007). Whilst there are inconsistencies between the findings of
transcriptomic studies and the precise biological mechanisms
involved in a disease situation there is no doubt that properly
designed studies which generate functionally verifiable results can
be invaluable in assisting in the description of the disease process
(Bolstad et al., 2004; Rosenfeld, 2010; Henriques and Gonzalez De
Aguilar, 2011). For the purposes of this review we concentrated
our attention upon articles that were found from a PubMed search
using the search terms microarray and ALS.
RNA QUALITY
A recurring dilemma in studies of gene expression in post mortem
tissue has been the residual debate concerning the quality of RNA
derived from such tissue and whether it is appropriate for these
studies. However, it is now accepted that gene expression studies
in post mortem tissue are possible as long as appropriate quality
control measures are followed (Harrison et al., 1995; Trabzuni
et al., 2011). For most model studies standardized procedures
can be set in place in order to reduce potential factors that
might cause RNA degradation but even in an established and
well organized human brain banking situation there are variables
relating to post mortem delay, agonal state and cause of death
all of which can affect RNA quality (Tomita et al., 2004; Popova
et al., 2008; Durrenberger et al., 2009; Trabzuni et al., 2011). As
indicated a number of studies have examined the effect of multiple
potential RNA degrading features but the overall consensus is that
providing adequate care is taken and good experimental design is
incorporated in order to eliminate gross differences between the
material being used then a reliable study can be carried out. In
order to monitor these potential confounding factors it is impor-
tant to control for any RNase introduction by carrying out all
experimental work in a clean and tidy environment using RNase
free materials. In addition it is essential that quality control steps
should be included to measure both quantity and quality of the
RNA being extracted and used (Copois et al., 2007; Wilkes et al.,
2010; Trabzuni et al., 2011). Spectrophotometric methods can be
used to measure nucleic acid quantity by examining absorbance
at 260 nm. This can give an indication of RNA quality and
the 260/280 ratio provides a measure of protein contamination
whilst the 260/230 ratio provides a measure of organic solvent
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carryover. However, these metrics do not give a clear idea of
RNA quality. For this, electrophoretic methods are required to
examine the RNA directly. In the past a denaturing agarose gel
(including formamide in the gel matrix) allowed the RNA to be
visualized following staining with ethidium bromide. However,
these methods required a large input of total RNA and have now
been largely superseded by capillary based methodology such as
the Agilent Bioanalyser and/or the TapeStation. In effect, both
these devices drive the RNA sample through a capillary and over
a laser which monitors absorbance at 260 nm over time hence
providing a profile of the absorbance which can be compared to
the profile of a molecular weight ladder run at the same time.
If total RNA is the test sample then one would expect a small
series of peaks at low molecular weight followed by the two
ribosomal RNA peaks (the smaller peaks might be removed if a
column based separation method is used). Software integral to
the machine is then able to calculate an RNA integrity number
(RIN) which is scaled from 0 to 10 and depends upon the ratio of
the 28S to 18S rRNA peaks and the amount of degraded material
that is present. It should be expected that for material derived
from tissue culture experiments that a high RIN value is routinely
achieved. However, post mortem human material is often quite
degraded and RIN values of around 4 might be measured. It
has been demonstrated in microarray, RNASeq and qRT-PCR
that these values do not preclude a valid experiment (Preece
et al., 2003). However, it is important to maintain equivalence
in the experimental material and endeavor to compare samples
of similar quality as well as support findings through appropriate
validation methodologies.
HUMAN STUDIES IN WHOLE TISSUE
Microarray studies on whole tissue generate an overview of
the gene expression profile of the whole tissue at the time of
the RNA collection. There have been a number of microarray
studies which were designed to examine some aspect of gene
expression changes in ALS by examining a particular tissue.
A very early study by Malaspina et al. (2001), used gridded
cDNA membrane arrays to examine the expression of 18,400
genes in the anterior horn of lumbar spinal cord from four
ALS cases and four controls (with a further four patients and
controls used as verification subjects). Fourteen transcripts were
identified as being significantly differentially expressed, and these
were shown to belong to processes relevant to ALS including;
oxidative stress and neuro-protection, motor neuron function,
lipid metabolism, neuroinflammation and anti-apoptotic factors.
This was an important demonstration of the potential of this
sort of study and whilst it depended upon a predefined group
of cDNAs that were present upon the array, the results gave an
overview of gene expression in the anterior horn of the lumbar
spinal cord. It also confirmed that post mortem tissue could
be used in such a study. Ishigaki et al. (2002) took a different
approach. Using lumbar spinal cord from 8 sporadic ALS cases
and controls they initially used one case and control for molec-
ular indexing which identified 576 cDNA fragments in the sALS
material that could be compared to the control to select identifiers
for further analysis. In this way spotted microarrays were prepared
for 84 cDNAs deemed to be differentially expressed between the
sALS and control individuals that were further examined on a
wider group of patients and controls. Ultimately six differen-
tially expressed genes were identified; four corresponded to pre-
viously known genes, 30-kDa TATA-binding protein-associated
factor (TAFII30), macrophage-inhibiting factor-related protein-8
(MRP8), metallothionein-3 (MT-3) and ubiquitin-like protein 5
(UBL5) whilst the remaining two were uncharacterized expressed
sequence tags. This was an interesting approach but the limited
numbers of genes identified made it difficult to identify processes
related to cell death.
An early study by Dangond et al. (2004), used Affymetrix
FL arrays to compare the expression profile of grey matter from
the lumbar spinal cord of seven ALS cases and four controls.
A robust analytical process identified 93 genes which discrim-
inated between the two groups. There was some attempt to
differentiate between sporadic and familial disease, however, the
numbers in the familial group made this analysis less robust. The
93 significant genes were subdivided into groupings defined by
known biological functions giving some 10 sub-groups includ-
ing; transcription and RNA binding, excitotoxicity, cell survival
and growth, neuronal function, inflammation, cell receptors and
signaling and stress response. Wang et al. (2006), examined the
motor cortex in five ALS cases compared to three controls using
the newer Affymetrix U133A Gene Chips containing 14,500 genes
for microarray analysis. They identified 275 significantly differ-
entially expressed genes, of which 265 were downregulated and
they were able to verify the changes in 22 of these genes by
quantitative real time polymerase chain reaction (QRT-PCR).
Interestingly different groups of genes seemed to be important in
sALS motor cortex compared to the spinal cord, but there were
similarities in that stress response and excitoxicity were featured
in both groups, as were features of mitochondrial metabolism.
Unfortunately, the different cell populations of the two regions
might be having a profound impact upon the data. A further study
of motor cortex (Lederer et al., 2007), used 11 sALS cases and
9 controls in an Agilent slide array based study. Fifty-seven genes
were identified as differentially expressed following the filtering
and pathway based analysis; 40 down and 17 upregulated. Such a
small group of genes were readily verifiable by alternative methods
and the list was compared to previous studies including that of
Dangond et al. (2004), and 14 genes showed a similar response.
Overall a very thorough analysis produced an interesting inter-
acting pathway diagram examining the interplay of differentially
expressed genes in the motor cortex of sALS individuals. It is
important to note that without describing individual genes it is
possible to discern similar patterns in the lists of genes differen-
tially expressed in the whole tissue experiments described here.
Recurrent themes are mitochondrial metabolism, excitotoxicity,
calcium homeostasis, protein turnover and neuronal maintenance
and signaling.
Using a different approach Offen et al. (2009) examined the
gene expression profile in spinal cord of sALS patients and com-
pared some of the changes to the Glycine 93 to Alanine (G93A)
SOD1 mouse model of fALS. In the study of four sALS cases com-
pared to four matched controls using the Clontech membrane
arrays, 60 gene changes were identified in the 1176 probe sets
available to be examined. On this occasion the genes identified
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were grouped into biological processes such as; apoptosis, protein
turnover, cell cycle functions, extracellular carrier/transport func-
tions, cytoskeletal and intracellular proteins and proteins relating
to transcription and translation. Six genes were further investi-
gated in the G93A SOD1 mouse model of fALS to determine
if the changes seen post mortem were recapitulated during the
lifespan of the mouse. These genes were; cathepsins B and D,
apolipoprotein E, epidermal growth factor receptor (EFGR), fer-
ritin and lysosomal trafficking regulator (LYST). These transcripts
did seem to increase with disease progression in the mouse model
suggesting some overlap between the human situation and the
mouse model which does add some credence to the use of the
model for human ALS.
Two recent studies have taken a quite different approach.
Bernardini et al. (2013), concentrated upon mitochondrial related
genes and Figueroa-Romero et al. (2012), tried to relate gene
expression changes to methylation events in the genome. The
Figueroa-Romero study was focussed on relating genome methy-
lation events to gene expression changes found in sALS spinal
cord. 12 sALS cases and 11 age and sex matched controls were
used to determine the methylated genetic regions using Illumina
Methylation 27 Bead Chips, whilst gene expression analysis was
carried out using the Affymetrix Human U133 Plus 2 GeneChips.
In the methylation chip assay 3574 regions associated with genes
were found to be differentially regulated. In the gene expression
study some 1182 genes were found to be differentially expressed in
the sALS spinal cord. When comparing the two datasets 51 genes
that were hypomethylated were upregulated and 61 genes that
were hypermethylated were downregulated. These concordant
“epigenes” could be functionally grouped into categories such
as; immune response, defence response, neuron adhesion and
plasma membrane. Overall this work suggested an epigenetic, or
environmental, influence upon the pathogenesis of sALS which
may be relevant to the process of cell survival. In the Bernardini
study they concentrated upon skeletal muscle which was a new,
but potentially relevant, tissue to examine. They hypothesized
that muscle degeneration might be functionally important in the
process of neurodegeneration and that differentially expressed
genes in this tissue could be key in the pathogenic process.
They examined quadriceps or biceps muscles in seven sALS cases
and seven age and sex-matched controls. A focussed Affymetrix
GeneChip array was used and using a fold change cutoff of
1 and p-value cutoff of 0.05, 96 differentially expressed genes
were identified. Unlike in previous studies on this occasion more
genes (80), were seen in the upregulated group. In total 13 genes
related to muscle structure were distinguished and when ontology
relationships were investigated using the DAVID software (Huang
da et al., 2009) platform, other genes were found to be grouped
in areas such as the actin cytoskeleton and glycogenesis, with
mitochondrial function also identified. Further studies would be
needed to determine the relevance of this work particularly with
regard to further subtyping of the ALS cases. A study by Shtilbans
et al. (2011) also looked at gene expression differences in muscle
biopsies from ALS cases and controls. The study was hampered in
that mixed groups of familial and sporadic cases were examined
and different muscle groups were included in mixed proportions
in each comparative group. The differences they found were in
genes related to muscle structure, the cytoskeleton and cellular
metabolism.
Two studies have used peripheral blood to look for gene
expression differences with the underlying hypothesis that
changes found in this tissue might reflect changes associated with
the disease as has been seen in other neurodegenerative diseases.
Saris et al. (2009) used whole blood and a designed analysis
tool to uncover disease specific differences whereas Mougeot
et al. (2011) isolated lymphocytes and examined these directly.
In the Saris study, the weighted co-expression analysis found that
genes in pathways related to apoptosis, the mitochondrion, stress
response, calcium binding ubiquitination and vesicle transport
were differentially expressed between the ALS patients and con-
trols. In contrast, Mougeot used an ontology relationship tool
called SAFE and found that a set of genes previously grouped
into an ALS related KEGG pathway were differentially expressed
in the lymphocytes. Genes in this pathway related to motor
neuron degeneration in ALS (KEGG:05014), and included SOD1,
caspases 1,3,9, neurofilament light, medium and heavy (NFL,
NFM and NFH), and N-methyl-D-Aspartate receptors GRIN 1,
2A, 2B, 2C and 2D. In addition, an ontology analysis based
upon individual genes identified changes in pathways related
to DNA metabolism, RNA splicing, mitochondrial function,
oxidation, endoplasmic reticulum,ubiquitin proteasome system,
post-transcriptional modification and neurological function. The
overall conclusion to be drawn from both studies in blood is
that although it is a peripheral tissue, it does show gene expres-
sion changes and pathways previously implicated by the use
of central nervous system (CNS) material, including apopto-
sis, mitochondria, RNA splicing and, surprisingly, neurological
function.
The studies of whole tissue have reached different conclusions,
perhaps as a result of using tissue from different stages of disease
and location, but there are common themes involved in the
processes that are found to be differentially expressed in the ALS
tissue which have been associated to motor neuronal cell death. In
particular these are apoptosis, oxidative stress, protein processing,
mitochondrial function and the cytoskeleton.
SINGLE CELL ANALYSIS OF HUMAN MOTOR NEURONS
The previous studies are valuable but they make it difficult to
determine the precise input of each cell. In order to obviate this,
several methods have been developed to examine the gene expres-
sion profile of individual cells isolated from tissue. Two recent
reviews have discussed the available methods for cell specific
transcriptome analysis (Kannanayakal and Eberwine, 2005; Okaty
et al., 2011), and we shall not discuss these further. In terms of
ALS, most studies seem to have adopted a laser capture microdis-
section approach. In 2005, Jiang et al. carried out a microarray
study of laser captured motor neurons from the lumbar region of
14 sporadic ALS cases and 13 controls (Jiang et al., 2005). They
used a PALM microdissector and applied the labeled RNA to BD
Atlas glass microarrays. They found 52 up and 144 down regulated
genes from the 4845 interrogated. Owing to the fact that they
compared the isolated spinal motor neurons data to ventral horn
spinal cord tissue data they were able to distinguish genes whose
differential expression was restricted to the motor neurons and
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which was not detected when the whole tissue was examined. It
was found that genes associated with cell death and cell signaling
were upregulated in the disease related motor neurons whereas
those associated with the cytoskeleton and transcription were
downregulated. This study provided information concerning gene
expression changes that were specific to the spinal cord motor
neurons and demonstrated the value of this approach over whole
tissue studies. Our group has carried out a number of published
studies examining the gene expression profile of motor neurons
isolated by laser capture microdissection in several models. In her
study in 2010, Cox et al. (2010) examined the differences between
three individuals who had charged multivesicular body protein
2B (CHMP2B) mutations leading to an ALS phenotype and
7 matched normal controls. Following gene expression analysis
using Affymetrix Human U133 Plus 2 GeneChips, 890 genes
were downregulated and 55 upregulated at a fold change cutoff
of 2 and p-value 0.05. These were categorized using DAVID
software into ontological groupings and groups associated with
axon guidance, regulation of actin cytoskeleton and soluble NSF
attachment protein receptor (SNARE) interactions in vesicular
transport, mammalian target of rapamycin (mTOR) signaling
and regulation of autophagy, mitogen activated kinase (MAPK)
signaling, calcium signaling, and cell cycle and apoptosis were
found to be the most enriched. Further functional studies were
able to confirm a dysfunction in the autophagy pathway in an in
vitro model. A further study (Kirby et al., 2011), examined gene
expression differences in cervical spinal motor neurons between
three fALS cases carrying SOD1 mutations and seven normal
controls using the Affymetrix Human U133 Plus 2 arrays. In total,
524 probe sets were found to be increased and 646 decreased.
These were characterized using the DAVID software package and
the major enriched categories were transcription, signaling and
metabolism. Importantly further investigations demonstrated the
relevance of the cell survival pathway involving PTEN/AKT in the
motor neurons with anti-apoptotic genes being downregulated
in the surviving motor neurons indicating an attempt by these
cells to mount a pro-survival response. Comparison of these
studies indicates that the different genetic variants have distinct
gene expression changes which ultimately lead to motor neuron
death.
In contrast to the case control scenario, Brockington et al.
(2013), examined features that distinguish the motor neurons
from the oculomotor nucleus and the lumbar spinal cord in
normal individuals to determine those features that enable the
oculomotor motor neurons to be selectively resistant to the cell
death undergone by spinal motor neurons in ALS. Tissue from
four neurologically normal individuals was collected and laser
capture microdissection used to isolate motor neurons from the
oculomotor nucleus and lumbar spinal cord. The labeled RNA
from these was applied to the Affymetrix Human U133 Plus 2
GeneChip. 1521 gene expression differences were identified as
being differentially expressed in the oculomotor neurons. Gene
ontology analysis determined that genes involved in synaptic
transmission, ubiquitin mediated protein degradation and mito-
chondrial oxidative phosphorylation were upregulated in ocu-
lomotor motor neurons; these pathways had shown decreased
expression in the ALS spinal cord and motor cortex in previous
studies. This work was supplemented by carrying out comparison
studies with other gene expression data derived from an online
database and the analysis showed that the differences observed in
human oculomotor neurons were also found in two other species
confirming that the oculomotor motor neurons had a partic-
ular profile of synaptic neurotransmitter receptors, particularly
gamma aminobutyric acid (GABA) and glutamate which made
them less vulnerable to excitotoxic cell death. Electrophysiological
studies complemented and supported this conclusion.
Again some common features can be derived that seem to
associate the differential expression of genes related to the mecha-
nisms of cell death. These include; cell signaling, autophagy, phos-
phatase and tensin homologue/protein kinase B (PTEN/AKT)
cell signaling pathway, ubiquitin and mitochondrial function,
cytoskeleton, transcription and apoptosis.
ANIMAL MODELS USING WHOLE TISSUE
Whilst human tissue can only be accessed at end stage, the use of
animal models allows progression of the disease to be monitored.
An early study by Yoshihara et al. (2002) examined the gene
expression differences between tissue homogenates of lumbar
spinal cord of G93A SOD1 versus non-transgenic littermates at
three ages; 7, 14 and 17 weeks corresponding to presymptomatic,
onset and end stage of disease. Using mouse Atlas arrays from
Clontech they found an upregulation of inflammatory related
genes associated with activated microglia and astrocytes. This was
induced by 11 weeks of age and continued to advance up to the
17 week time point.
Fukada et al. (2007) examined the gene expression profile
of whole spinal cord from two time points, presymptomatic
(98 days) and post symptomatic (154/176 days), in a differ-
ent mutant SOD1 transgenic model carrying the L126delTT
mutation. They used the AceGeneMouse Oligo Chip. At the
presymptomatic stage 11 genes were upregulated and two down-
regulated at a fold change of greater than two whilst at the post-
symptomatic stage 54 were upregulated and four downregulated.
With such small numbers of differences ontological relationships
were hard to carry out and since whole spinal cord was examined
the precise relationship of the gene changes to the disease process
is difficult to disentangle.
It is thought that physical exercise might have a beneficial effect
upon disease progression in ALS and two studies investigated this
using microarrays and mouse models (Ferraiuolo et al., 2009;
Hashimoto et al., 2009). Hashimoto et al. (2009) examined the
response to exercise in normal mice by subjecting the mice to two
exercise regimes; a single burst of 30 min exercise or 2 weeks of
30 min exercise per day on a treadmill. Whole spinal cord RNA
was examined using the OpArray Mouse V4 array from Operon.
Only a small number of changes in gene expression were identi-
fied; after the single burst of exercise 3 genes were upregulated and
29 downregulated whilst following the extended exercise regime
1 gene was found to be increased and 13 decreased. As seen in
some previous studies the numbers are rather small for pathway
analysis and since whole tissue has been studied it is difficult
to dissect out precise effects. Ferraiuolo et al. (2009) examined
the gene expression changes in gastrocnemius muscle as well as
motor neurons isolated from lumbar spinal cord of three female
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mice subjected to a voluntary exercise regime of 21 days on a
running wheel compared to three sedentary mice. Data were also
collected concerning the exercise behavior of the mice. In the
muscle tissue, 194 genes were upregulated and 176 downregulated
using the same parameters. These genes were functionally found
to be associated with vascularization and myogenic processes
involved with extracellular matrix reorganization. The profiles
exhibited by the gastrocnemius muscle are representative of the
mixed cell population of the whole tissue and indicate some
overall changes in the muscle as a response to the exercise regime.
Overall, 203 genes were upregulated and 241 down at a fold
change of at least two and p-value of 0.05 or less in the motor
neurons. Functionally these genes were categorized into signaling,
cytoskeleton and transcription regulation. The response of the
motor neurons to exercise was similar to that of hippocampal
neurons to repetitive stimulation, akin to a long term poten-
tiation. There is a body of evidence that links exercise to the
processes of cell death observed in ALS. This work goes some
way to highlight similarities between the physiological response
of MNs and skeletal muscle to exercise and the pathophysiology
of ALS.
Two recent studies from the same group (Chen et al., 2010;
Hu et al., 2013), have used Mouse Exon 1 arrays from Affymetrix
to examine gene expression changes and alternative splicing in
the G93A SOD1 mouse model. In the first study they examined
animals at onset versus litter mate controls and in the second
study 30 day transgenic mice were compared to litter mate con-
trols of the same age and 120 day transgenic mice. They examined
both differential expression and alternative splicing events. There
were only 202 differentially expressed genes with a p-value cutoff
of 0.05 found when comparing the 30 day old transgenic to
nontransgenic mice but only one of these was at a fold change of
> 2. There were in total 2869 differentially expressed genes events
found when comparing the 120–30 day transgenic mice with
263 up and 71 down when a fold change of two and p-value of
< 0.05 was imposed. Gene ontology analysis of the differentially
expressed genes revealed that pathways involving cytokine recep-
tor, cell adhesion, haematopoesis, and cell signaling included the
most genes. In the onset group 322 transcripts were differentially
expressed with 309 upregulated in the transgenic group when of
a fold change of two and p < 0.05 was applied. Similar pathways
were identified in this study to the previous one. In both studies
a splicing index analysis was carried out in order to determine
the levels of alternatively spliced transcripts. Comparing the 120
day transgenic to 30 day control 563 transcripts were alternatively
spliced, of which 537 were considered as exon inclusion events,
whilst only 85 alternative splicing events were identified in the 30
transgenic versus 30 day control comparison and on this occasion
61 were classified as exon inclusion. When the splicing data
was examined by pathway analysis it was interesting that similar
pathways were highlighted as found in the differentially expressed
genes analysis. The data was interpreted to demonstrate that as the
disease progressed then an increased number of splicing changes
were seen. To some extent this is borne out by the onset study
where 333 probe sets showed an altered splicing index indicating
possible alternative splicing. However, the comparison of 120 day
transgenic mice versus controls is missing which would allow a
better comparison relative to normal ageing effects. Whilst some
qRTPCR validation was completed the studies represent early
work in using the exon arrays to examine the changes invoked by
the presence of the G93A SOD1 mutation on alternative splicing
events.
The studies discussed thus far have used mouse models but
Hedlund et al. (2010) used the G93A SOD1 rat model for a
study of selective motor neuron vulnerability. They quantified
the extent of motor neuron loss in different motor neuron
nuclei; oculomotor and trochlear (CN3/4), facial (CN7), trigem-
inal (CN5), hypoglossal (CN12) and cervical spinal cord in the
transgenic model. This directed the laser capture studies where
motor neurons were collected from the CN3/4, CN12 and cervical
spinal cord of normal rats and applied the isolated RNA to whole
genome rat microarrays (Rat 230 2 Affymetrix). The microarray
analysis showed that the more vulnerable motor neurons of the
cervical spinal cord and hypoglossal nerve were more similar than
either group compared to the less vulnerable CN3/4 motor neu-
rons. There were interesting differences in Hox gene expression
between the motor neuronal groups which were concomitant to
the relative positions of the neurons in the anterior to posterior
axis. There were also differences in RNA processing between the
groups which also seemed to relate to the known association of
RNA processing genes with ALS (Baumer et al., 2010). This report
highlighted the usefulness of alternative animal models for the
study of ALS and took an interesting approach to uncovering
some of the underlying differences between selectively vulnerable
and resistant motor neurons.
Dupuis and Loeffler (2009) examined neuromuscular changes
in transgenic models of ALS. This led from the observation
that the first event in the disease process seen in the transgenic
mouse model of ALS is the destruction of the neuromuscular
junction. Hence, studies concentrating upon the motor neurons
may be identifying effects rather than cause of disease. However,
it must be borne in mind that the SOD1 mouse model represents
an overexpression model of disease and that SOD1 mutations
correspond to only 2% of all ALS.
Finally in this section, Kumimoto et al. (2013) have undertaken
to study ALS in a Drosophila model. They used a GAL4-UAS
promoter to drive expression of wild type Drosophila SOD1 or
the human SOD1 mutation glycine 85 to arginine (G85R) in
motor neurons and glia. They carried out microarray analysis
upon whole flies 5 days old (young), and 45 days (old), using
the Drosophila 2 GeneChips from Affymetrix. They used several
analyses to examine gene expression changes at the different ages
and in the different cell types as well as a meta-analysis to uncover
general changes. The mutant SOD1 G85R in motor neurons
alone caused 58 gene expression changes (33 up) at 5 days and
102 transcripts (73 up) at 45 days whereas in glia alone these
numbers were 65 (33 up) and 105 (57 up) respectively. When
the transgene was expressed in both cell types simultaneously the
numbers were; 70 (34 up), and 83 (38 up). The overexpression of
G85R SOD1 in the cells of the Drosophila caused changes in gene
expression in oxidative stress, mitochondria, lipid metabolism
and neurodevelopmental and signaling genes. Since the microar-
ray analysis was carried out upon whole flies it is again difficult to
determine the precise cellular effect of the overexpression strategy
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but there were commonalities in the pathways implicated with
previous microarray studies and the impression is that the study
offers a new model approach to understanding ALS. Since these
studies were somewhat varied in the animal models, the tissue
being investigated and the number of genetic changes identified
it is difficult to describe common themes in the gene expression
changes being seen and their relationship to cell death. However,
cell signaling, mitochondrial dysfunction and oxidative stress
continue to be implicated in the pathogenesis of ALS in animal
models.
SINGLE CELL ANALYSIS OF NON-HUMAN MODEL MOTOR
NEURONS
Perrin et al. (2005) combined laser capture dissection with
microarray to examine gene expression in the spinal cord motor
neurons of the G93A SOD1 mice. Lumbar spinal motor neurons
from male mice at presymptomatic (60 days), onset (90 days) and
end stage of disease (120 days) were analyzed using the Mouse
430 2 GeneChip from Affymetrix. At 60 days only 27 genes were
differentially expressed with this number increasing to 150 at
90 days and more than 400 by 120 days. At all the time points
more genes were found to be upregulated in the G93A SOD1 mice;
17, 95 and 389 respectively. Thirteen of these transcripts were
found to be differentially expressed at all stages. A similar study
from our group (Ferraiuolo et al., 2007), looked at the effect of
both the G93A SOD1 and the wild type SOD1 compared to non-
transgenic littermate controls on a homogeneous background of
C57bl6. Few changes were seen in motor neurons isolated from
the WTSOD1 mice but 252 genes were differentially expressed
at 60 days (234 upregulated), 51 at 90 days (32 up) and 167 at
120 days (81 up), in the G93A SOD1 mice. These changes at
the presymptomatic, symptomatic and end stage of the disease
process in the mice indicate that at an early time point the motor
neurons try to mount a metabolic response to the burgeoning
disease process by upregulating several pathways. However, by
the endstage, this process having failed, the cells appear to try
to re-enter the cell cycle which is a doomed response. There
are notable differences between the two studies in terms of the
overall changes in gene expression profile, although both groups
do see changes in the intermediate filament protein vimentin,
it is likely that the differences might relate to the actual genetic
background of the mice being used, the transgene copy number
and also the analytical processes used in examining the data.
A study by Saxena et al. (2009) took a different approach to
examine the matter of selective vulnerability of motor neurons.
They injected RITC-dextran into the gastrocnemius or soleus
muscles and following retrograde transport they were able to
identify and selectively isolate the motor neurons associated with
the vulnerable phenotype which project to the fast fibre gastroc-
nemius muscle and those that are relatively resistant and project
to the soleus muscle which has fatigue resistant or slow fibres. The
RNA isolated from the selectively microdissected motor neurons
was applied to the Mouse 430 2 arrays from Affymetrix. The
longitudinal study showed that the vulnerable motor neurons
are selectively prone to endoplasmic reticulum stress and a pro-
gressive failure to mount a proper unfolded protein clearance
response.
This group of studies are more focussed and underline the
importance of the single cell analysis at different stages of disease
progression.
SINGLE CELL ANALYSIS OF NON-HUMAN NON-MOTOR
NEURON CELL TYPES
Using the G93A Mutant SOD1 mouse model Ferraiuolo et al.
(2011) attempted to examine the relationship between motor
neurons and astrocytes in this model of disease (Ferraiuolo
et al., 2011). Astrocytes were collected from lumbar spinal cord
of three male 60 day old mice and three non transgenic litter
mate controls, and the labeled RNA applied to Mouse 430 2
Gene Chips from Affymetrix. 583 transcripts were found to be
upregulated 526 downregulated in the G93A SOD1 astrocytes.
Ontological analysis showed that multiple transcripts associated
with carbohydrate metabolism were differentially expressed and
an overall decline in the activity of the lactate shuttle was
described in the mutant astrocytes indicating an inability to
support the metabolic requirements of the motor neurons. The
altered metabolism was further investigated and it was shown
that non-transgenic motor neurons grown on G93A SOD1 astro-
cytes demonstrated an increase in the ratio between pro- nerve
growth factor and mature nerve growth factor (NGF) which
was associated with an over-expression of the p75 receptor
for NGF. Hence it was shown that the G93A SOD1astrocytes
provided reduced metabolic support to the motor neurons as
a result of the downregulation of the lactate shuttle and the
activation of the p75 receptor and these factors contributed to
the toxicity of the mutant astrocytes to the co-cultured motor
neurons.
CELL CULTURE MODEL STUDIES
Two studies have examined the gene expression profile of the NSC
34 cells carrying different human SOD1 mutations. The first study
(Kirby et al., 2002), utilized a designed membrane microarray
from Clontech with cDNAs for just 588 genes. The experiment
was carried out on cells carrying G93A, G85R or isoleucine 113
to threonine (I113T) SOD1 mutations at basal conditions and
cells which had undergone stress exerted by serum withdrawal.
At the basal condition differences were seen in the numbers of
differentially expressed genes for the different SOD1 mutation
but a combined analysis showed only 29 genes to be differentially
expressed as a result of the SOD1 mutation with seven being
downregulated. Very few genes were found to be differentially
expressed following the induction of a stress imposed by serum
withdrawal which might be a result of the analytical stringency
being applied. In a subsequent study (Kirby et al., 2005), a
comparison was made between NSC34 cells expressing G93A
mutant SOD1 and those expressing wild type human SOD1. On
this occasion the mouse U74Av2A GeneChip from Affymetrix
was used. At a fold change of two with a p-value of 0.05, 268
transcripts were differentially regulated in the presence of mutant
SOD1, of which 197 were downregulated. Following thorough
ontological analysis it was found that the presence of the mutant
SOD1 caused a significant down-regulation of the cells capacity
to deal with oxidative stress. In particular the group of genes
with an antioxidant response element in their promoter, termed
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programmed cell life genes, which would be activated by the tran-
scription factor nuclear factor (erythroid-derived) like 2 (Nrf2)
were downregulated indicating a failure of the cells to mount a
proper therapeutic antioxidant stress response. Subsequent work
by Mead et al. (2013) has demonstrated that induction of the Nrf2
response by S(+)-Apomorphine improves the motor function of
the G93A SOD1 mice underlining the importance of increasing
the expression of the programmed cell life genes in a therapeutic
strategy to treat ALS.
Vargas et al. (2008) isolated primary astrocytes from both
G93A SOD1 mutant and normal littermate control embryonic
rats and examined the profile of gene expression using Rat
genome 230 2 arrays from Affymetrix. A total of 81 transcripts
were differentially expressed by the mutant SOD1 bearing astro-
cytes with 55 being upregulated. The genes were characterized
according to their biological function and were separated into
groups; extracellular matrix and cell migration, signaling and
receptor activity, transcription, cell proliferation, response to
stress, oxidoreductase activity, catalytic activity and unknown. It
is interesting to note that despite the fact that different cell types
are being investigated there are some similarities in the effect of
the SOD1 mutation in astrocytes and motor neurons from mice
and rats.
In the study by Boutahar et al. (2011) they derived primary
cortical motor neurons from transgenic mice either with or
lacking the G93A SOD1 mutation. The cells were derived from
E14 embryos and maintained in culture for a brief period until
the presence of the transgene was confirmed. Some cultures were
subjected to stress with hydrogen peroxide or NMDA treatment.
Microarrays using Mouse 430 2 GeneChips from Affymetrix were
carried out and the results analyzed to determine fold changes
of two or more. In the untreated cells 260 transcripts were
differentially regulated with 70 upregulated. Following hydrogen
peroxide treatment the number was 163 with 59 upregulated
and following NMDA treatment 181 with 62 upregulated. Few
genes were shared between the three treatments. Gene ontological
analysis showed an increase in transcripts associated with the
proteasome, some associated with autophagy and cytoskeletal
organization and axonal transport. There was some downregu-
lation in transcripts associated with ion transport. It was noted
that the presence of the transgene alone increased cell death but
this process was mitigated when the additional stresses, hydrogen
peroxide or NMDA, were introduced. Hence they identified a
small group of genes which were upregulated in the untreated
G93A cells but downregulated following the introduction of an
additional stress. These genes were; Cathepsin H,(CSTH) and
Autophagy related 4 homolog D (ATG4D) which are involved
in protein degradation, tubulin beta-4B chain (TUBB2C) and
Rho guanine nucleotide exchange factor 11 (ARHGEF11) which
are cytoskeletal, cell division cycle 25 homolog (CDC25) which
is involved in cell cycle regulation, solute carrier 7 (SLC7A12),
DEAD box 43 (DDX43) and leucine rich recognition motif 4
(LRRTM4) which are involved in the transmembrane domain and
transcripts ACN9, SSBP9 and TRIM36 involved in transcription
regulation.
The studies in cellular culture models all seem to underline the
importance of oxidative stress in the pathogenesis of ALS and the
difficulty that cells containing mutant SOD1 have in dealing with
this metabolic insult.
SYSTEMS BIOLOGY
Some studies have taken a more broad brush approach to the
analysis of microarray data and attempted to incorporate data
from a number of sources. Kudo et al. (2010) developed an
integrative approach to examine post mortem human material,
mouse models and microarray methods. They used the mouse
models of ALS, G93A SOD1 and frontotemporal dementia (FTD),
P30L Tau and isolated both motor neurons and glia for microar-
ray analysis. Using Agilent whole mouse genome microarrays
251 transcripts were identified as being differentially expressed
in at least one of the four comparisons. Of these 186 corre-
sponded to known genes and ontological analysis revealed that the
most enriched biological processes were associated with protein
modification/phosphorylation, signaling, regulation of muscle
contraction, stress response, the immune system and cell com-
munication. The data were confirmed both in further murine
tissue by semi-quantitative PCR and in human tissue from sALS
cases with tissue microarrays. Hence they used complementary
methodology to identify common mechanisms in the SOD1 and
TAU mouse models of motor neuron degeneration and human
sALS. The genes CNGA3, CRB1 and OTUB2 were common to
all the models and CNGA3, CRB1, OTUB2, SLK, DDX58, RSPO2
and MMP14 were related to sALS. In addition, 13 transcripts
found differentially regulated in the SOD1 motor neurons were
also found to be altered in their expression in the blood of G93A
SOD1 mice.
Baciu et al. (2012) adopted a reanalysis approach where they
performed an in depth analysis of a microarray experiment
carried out using purified peripheral blood lymphocytes from
11 ALS patients and 11 age matched controls. The RNA had been
interrogated using Agilent 4 × 44k human arrays and the authors
used a modified BaFL pipeline and at the same time a severe TM4
statistical analysis to remove potential confounding probes sets
and “purify” the dataset. The methodology was validated using
a previous dataset carried out using similar microarrays and a
coronary heart disease study. By carrying out the two different
analytical methods the authors attempted to account for errors
that might be inherent to either alone. Ultimately, a series of seven
genes was identified as being upregulated in the sALS patients,
were common to both methods and were verifiable by qRTPCR.
These genes were; B2M, ACTG1, DYNLT1, SKIV2L2, C12orf35,
TARDBP and ILKAP (which cross-hybridises with TARDBP).
A recent meta-analysis from Saris et al. (2013) looked to exam-
ine the datasets from a number of different microarray studies of
both murine and human material. They included seven human
studies; three of lumbar cord, two cervical cord and two motor
cortex. In addition there were nine studies of transgenic mouse
model material; seven of G93A SOD1, one L126delTT SOD1 and
one study of the progressive motor neuropathy and wobbler mice.
As the authors conclude, despite the variety of input material and
different array platforms used, there was a level of consistency in
the altered gene expression output. Hence they found altered gene
expression in the areas of protein turnover, immune response
and apoptosis in both human and murine studies. The mouse
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studies also showed consistent differences in genes involved in the
lysosome, metal ion binding and mitochondrial function. This
study is an interesting new approach to attempt to summate all
the data that has been produced thus far. There are likely to
be further assays of this type which will take advantage of the
large datasets in order to generate informative data with greater
statistical power owing to the larger numbers of samples being
included.
CONCLUDING REMARKS
This short review has attempted to summarize the depth of
study that has been carried out using transcriptomic technology
to examine the gene expression changes that can be identified
in comparisons of ALS tissue and controls. With the variety of
studies that have been done it is quite difficult to accurately
summarize the information but some overall differences can be
seen. In terms of mechanisms that have been uncovered in these
studies that are influential in the processes that underlie cell death
in ALS it can be seen that certain pathways are repeatedly enriched
as a consequence of the disease process. These include; oxidative
stress, mitochondrial function, apoptosis, cytoskeleton, neuroin-
flammation and protein processing. It is interesting to note that
when peripheral tissues have been used similar processes have
been identified as distinguishing the material from individuals
with disease. Whilst many of the studies delineated differences
between disease and control at the level of the transcriptome an
important development has been developing functional studies
to demonstrate the validity of the identified changes and then
subsequent studies to investigate mechanisms to ameliorate them.
It is likely that the use of the microarray technology is likely to
become more of an adjunct to support a body of work as seen in
the study from Egawa et al. (2012). In this case the transcriptomic
element of the work was used to characterize human induced
pluripotent stem cells derived from dermal fibroblasts of normal
individuals and several TDP43 mutants. In the past we have seen
the transcriptomic study as being the lead in the experimental
approach but on this occasion the development of the induced
stem cells was the primary goal and the microarray analysis was
simply a tool to assist in the characterization of derived cells and
define potential routes for drug intervention. It is likely that with
the maturity and confidence that several years of transcriptomic
research have generated this type of approach will become more
widespread.
A further development in the examination of gene expression
differences between tissues is going to be the use of next gener-
ation sequencing to examination gene expression directly rather
than as an indirect measure based upon manufactured probes.
The next generation sequencing methodology provides a more
detailed examination of the transcriptome which allows for a
more in depth examination of novel transcripts, splice junctions
and non-coding RNAs in a single step rather than having to
carry out multiple different array experiments. As with the early
microarray work there is not yet a defined analytical pathway
for interpreting the data from RNA Seq experiments but this is
progressing rapidly. There is evidence that the two tools are being
used in a combinatorial approach (Kogenaru et al., 2012).
Transcriptomics has been used successfully to investigate the
mechanisms underlying the processes of cell death and has pro-
vided insights into the pathways that may be dysregulated. As the
tools are becoming more established it is likely that more studies
will use them to assist in the functional studies needed to develop
new treatments for ALS.
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